for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Catabasis Pharma & Sarepta Therapeutics to collaborate in Duchenne muscular dystrophy

Sept 29 (Reuters) - Catabasis Pharmaceuticals Inc :

* Collaboration to study exon skipping treatment by Sarepta with co’s oral NF-KB inhibition treatment in mouse model of DMD

* Catabasis Pharmaceuticals and Sarepta Therapeutics announce a joint research collaboration in Duchenne muscular dystrophy

* Collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy Source text for Eikon: Further company coverage: ;))

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up